Pricing

Checkmate Pharmaceuticals, Inc. (CMPI)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Alan Bash
Employees:
30
245 MAIN STREET, 2ND FLOOR, CAMBRIDGE, MA, 02142
978-503-2124

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Are you looking for this stock instead?

Checkmate Pharmaceuticals, Inc. develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available